Modification of Paclitaxel-loaded Solid Lipid Nanoparticles with 2-hydroxypropyl-β-cyclodextrin Enhances Absorption and Reduces Nephrotoxicity Associated with Intravenous Injection

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Sep 9

PMID 26347363

Citations 11

Authors

Jong-Suep Baek

Ju-Heon Kim

Jeong-Sook Park

Cheong-Weon Cho

Affiliations

Soon will be listed here.

Abstract

Background: Paclitaxel (PTX) solid lipid nanoparticles (SLNs) modified with 2-hydroxypropyl-β-cyclodextrin (HPCD) were evaluated for their ability to enhance PTX absorption and reduce the nephrotoxicity accompanying intravenous administration.

Methods: PTX-loaded SLNs (PS) and PTX-loaded SLNs modified using HPCD (PSC) were prepared by hot-melted sonication. The anticancer activity of PSC was evaluated in MCF-7 cells, and confocal microscopy was used to quantify the cellular uptake. The pharmacokinetic profiles of PTX released from PSC after intravenous administration were studied in rats. Furthermore, kidney toxicity was determined by measuring the kidney size and plasma creatinine level.

Results: PSC were successfully prepared by hot-melted sonication and had smaller diameters than PS. PSC exhibited improved anticancer activity and cellular uptake in MCF-7 cells. Furthermore, PSC showed higher bioavailability in rats after intravenous administration than PTX solution; however, no significant differences in kidney toxicity were observed.

Conclusion: Based on these results, PSC could be considered as a potential therapeutic PTX delivery system for breast cancer with low renal toxicity.

Citing Articles

Cyclodextrin Drugs in Liposomes: Preparation and Application of Anticancer Drug Carriers.

Feng L, Wei R, Wu J, Chen X, Wen Y, Chen J AAPS PharmSciTech. 2024; 26(1):3.

PMID: 39638889 DOI: 10.1208/s12249-024-02999-0.

Lipid-core nanocapsules containing simvastatin do not affect the biochemical and hematological indicators of toxicity in rats.

Lorenzoni R, Davies S, Cordenonsi L, Roggia I, Vicosa J, Mezzomo N Toxicol Res (Camb). 2024; 13(6):tfae189.

PMID: 39539252 PMC: 11557222. DOI: 10.1093/toxres/tfae189.

Macrocycle-Based Supramolecular Drug Delivery Systems: A Concise Review.

Yang Y, Li P, Feng H, Zeng R, Li S, Zhang Q Molecules. 2024; 29(16).

PMID: 39202907 PMC: 11357536. DOI: 10.3390/molecules29163828.

Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment.

German-Cortes J, Vilar-Hernandez M, Rafael D, Abasolo I, Andrade F Pharmaceutics. 2023; 15(3).

PMID: 36986692 PMC: 10056426. DOI: 10.3390/pharmaceutics15030831.

Paclitaxel-Loaded Lipid-Coated Magnetic Nanoparticles for Dual Chemo-Magnetic Hyperthermia Therapy of Melanoma.

Oliveira R, Cintra E, Sousa-Junior A, Moreira L, da Silva A, de Souza A Pharmaceutics. 2023; 15(3).

PMID: 36986678 PMC: 10055620. DOI: 10.3390/pharmaceutics15030818.

References

Yamazaki M, Ito T . Deformation and instability in membrane structure of phospholipid vesicles caused by osmophobic association: mechanical stress model for the mechanism of poly(ethylene glycol)-induced membrane fusion. Biochemistry. 1990; 29(5):1309-14. DOI: 10.1021/bi00457a029. View

Lameire N, Van Biesen W, Vanholder R . Acute renal failure. Lancet. 2005; 365(9457):417-30. DOI: 10.1016/S0140-6736(05)17831-3. View

Dordunoo S, Jackson J, Arsenault L, Oktaba A, Hunter W, Burt H . Taxol encapsulation in poly(epsilon-caprolactone) microspheres. Cancer Chemother Pharmacol. 1995; 36(4):279-82. DOI: 10.1007/BF00689043. View

Souto E, Muller R . Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008; 30(3):157-65. DOI: 10.1111/j.1468-2494.2008.00433.x. View

Prokop A, Davidson J . Nanovehicular intracellular delivery systems. J Pharm Sci. 2008; 97(9):3518-90. PMC: 3747665. DOI: 10.1002/jps.21270. View

Gratton S, Ropp P, Pohlhaus P, Luft J, Madden V, Napier M . The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008; 105(33):11613-8. PMC: 2575324. DOI: 10.1073/pnas.0801763105. View

Montazeri Aliabadi H, Shahin M, Brocks D, Lavasanifar A . Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharmacokinet. 2008; 47(10):619-34. DOI: 10.2165/00003088-200847100-00001. View

Sharma D, Chelvi T, Kaur J, Chakravorty K, De T, Maitra A . Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res. 1996; 8(7-8):281-6. View

Sharma A, Mayhew E, Straubinger R . Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 1993; 53(24):5877-81. View

10.

Shimeda Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T . Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005; 28(9):1635-8. DOI: 10.1248/bpb.28.1635. View

11.

Koziara J, Whisman T, Tseng M, Mumper R . In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release. 2006; 112(3):312-9. DOI: 10.1016/j.jconrel.2006.03.001. View

12.

Lee S, Huh K, Lee J, Cho Y, Galinsky R, Park K . Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules. 2007; 8(1):202-8. PMC: 2532792. DOI: 10.1021/bm060307b. View

13.

Bilensoy E, Gurkaynak O, Dogan A, Hincal A . Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm. 2007; 347(1-2):163-70. DOI: 10.1016/j.ijpharm.2007.06.051. View

14.

Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L . Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008; 355(1-2):321-7. DOI: 10.1016/j.ijpharm.2007.12.016. View

15.

Lippacher A, Muller R, Mader K . Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int J Pharm. 2000; 196(2):227-30. DOI: 10.1016/s0378-5173(99)00428-7. View

16.

Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco M . Scale-up of the preparation process of solid lipid nanospheres. Part I. Int J Pharm. 2000; 205(1-2):3-13. DOI: 10.1016/s0378-5173(00)00471-3. View

17.

Mehnert W, Mader K . Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3):165-96. DOI: 10.1016/s0169-409x(01)00105-3. View

18.

Moghimi S, Hunter A, Murray J . Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53(2):283-318. View

19.

Kim S, Kim D, Shim Y, Bang J, Oh H, Wan Kim S . In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001; 72(1-3):191-202. DOI: 10.1016/s0168-3659(01)00275-9. View

20.

Singla A, Garg A, Aggarwal D . Paclitaxel and its formulations. Int J Pharm. 2002; 235(1-2):179-92. DOI: 10.1016/s0378-5173(01)00986-3. View